107 related articles for article (PubMed ID: 15474322)
21. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
22. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
Wagenlehner FM; Lehn N; Witte W; Naber KG
Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
[TBL] [Abstract][Full Text] [Related]
24. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus].
Kouda M; Homma S; Udagawa I; Tamura K; Fukuhara J; Takeuchi M
Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023
[TBL] [Abstract][Full Text] [Related]
25. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
27. Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill.
Lin G; Pankuch GA; Appelbaum PC; Kosowska-Shick K
Diagn Microbiol Infect Dis; 2012 Jul; 73(3):287-9. PubMed ID: 22575272
[TBL] [Abstract][Full Text] [Related]
28. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
29. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients.
Castagnola E; Amoroso L; Banov L; Faraci M; Loy A; Moscatelli A; Risso F; Barabino P; Ciucci A; Bandettini R
J Chemother; 2014 Oct; 26(5):273-5. PubMed ID: 24070064
[TBL] [Abstract][Full Text] [Related]
30. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
31. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin.
Smith K; Perez A; Ramage G; Gemmell CG; Lang S
Int J Antimicrob Agents; 2009 Apr; 33(4):374-8. PubMed ID: 19101124
[TBL] [Abstract][Full Text] [Related]
32. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
Papadimitriou-Olivgeris M; Kolonitsiou F; Zerva L; Lebessi E; Koutsia C; Drougka E; Sarrou S; Giormezis N; Vourli S; Doudoulakakis A; Konsolakis C; Marangos M; Anastassiou ED; Petinaki E; Spiliopoulou I
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):386-8. PubMed ID: 26341703
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
35. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López-Fabal F; Gómez M;
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):373-9. PubMed ID: 21683269
[TBL] [Abstract][Full Text] [Related]
36. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
[TBL] [Abstract][Full Text] [Related]
37. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
Lepak A; Marchillo K; VanHecker J; Andes D
Antimicrob Agents Chemother; 2015 Dec; 59(12):7833-6. PubMed ID: 26392492
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
Rouse MS; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212
[TBL] [Abstract][Full Text] [Related]
39. Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
Hajdu S; Holinka J; Reichmann S; Hirschl AM; Graninger W; Presterl E
Antimicrob Agents Chemother; 2010 Oct; 54(10):4078-84. PubMed ID: 20679509
[TBL] [Abstract][Full Text] [Related]
40. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
